EA200970386A1 - Бифенилсульфонильные и фенилгетероарилсульфонильные модуляторы гистаминового н3-рецептора, используемые для лечения ассоциированных с ним расстройств - Google Patents

Бифенилсульфонильные и фенилгетероарилсульфонильные модуляторы гистаминового н3-рецептора, используемые для лечения ассоциированных с ним расстройств

Info

Publication number
EA200970386A1
EA200970386A1 EA200970386A EA200970386A EA200970386A1 EA 200970386 A1 EA200970386 A1 EA 200970386A1 EA 200970386 A EA200970386 A EA 200970386A EA 200970386 A EA200970386 A EA 200970386A EA 200970386 A1 EA200970386 A1 EA 200970386A1
Authority
EA
Eurasian Patent Office
Prior art keywords
histamine
receptor
disorders
drowsiness
pharmaceutical compositions
Prior art date
Application number
EA200970386A
Other languages
English (en)
Inventor
Винсент Дж. Сантора
Райан М. Харт
Джейсон Б. Ибарра
Дуглас М. Парк
Альберт С. Рен
Грейм Сэмпл
Джеффри А. Шульц
Брайан Смит
Джеффри Смит
Original Assignee
Арена Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Арена Фармасьютикалз, Инк. filed Critical Арена Фармасьютикалз, Инк.
Publication of EA200970386A1 publication Critical patent/EA200970386A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/323—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Настоящее изобретение относится к некоторым бифенилсульфонамидным производным формулы (1а) и их фармацевтическим композициям, которые модулируют активность гистаминового НЗ-рецептора. Соединения по настоящему изобретению и их фармацевтические композиции предназначены для способов, применимых для лечения гистамин-НЗ-ассоциированных расстройств, таких как когнитивные расстройства, эпилепсия, травма головного мозга, депрессия, ожирение, нарушения сна и бодрствования, такие как нарколепсия, синдром работы по сменному графику, сонливость в виде побочного эффекта от медикаментозного лечения, поддержание внимания для содействия завершению задач и т.п., катаплексия, гиперсомния, синдром сонливости, нарушение суточного ритма организма, приступы апноэ во сне и т.п., синдром дефицита внимания с гиперактивностью (СДВГ), шизофрения, аллергии, аллергические реакции верхних дыхательных путей, аллергический ринит, заложенность носа, деменция, болезнь Альцгеймера и т.п.
EA200970386A 2006-10-17 2007-10-16 Бифенилсульфонильные и фенилгетероарилсульфонильные модуляторы гистаминового н3-рецептора, используемые для лечения ассоциированных с ним расстройств EA200970386A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85261006P 2006-10-17 2006-10-17
US93435807P 2007-06-11 2007-06-11
PCT/US2007/022086 WO2008048609A1 (en) 2006-10-17 2007-10-16 Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine h3-receptor useful for the treatment of disorders related thereto

Publications (1)

Publication Number Publication Date
EA200970386A1 true EA200970386A1 (ru) 2009-10-30

Family

ID=39149258

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970386A EA200970386A1 (ru) 2006-10-17 2007-10-16 Бифенилсульфонильные и фенилгетероарилсульфонильные модуляторы гистаминового н3-рецептора, используемые для лечения ассоциированных с ним расстройств

Country Status (16)

Country Link
US (1) US20100240653A1 (ru)
EP (1) EP2074086B1 (ru)
JP (1) JP2010506918A (ru)
KR (1) KR20090069333A (ru)
AR (1) AR063226A1 (ru)
AT (1) ATE512948T1 (ru)
AU (1) AU2007313180A1 (ru)
CA (1) CA2665204A1 (ru)
CL (1) CL2007002977A1 (ru)
EA (1) EA200970386A1 (ru)
IL (1) IL197892A0 (ru)
MX (1) MX2009004071A (ru)
PA (1) PA8750901A1 (ru)
PE (1) PE20081462A1 (ru)
TW (1) TW200823204A (ru)
WO (1) WO2008048609A1 (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1558582E (pt) 2003-07-22 2006-05-31 Arena Pharm Inc Derivados de diaril- e aril-heteroaril-ureia como moduladores do receptor de serotonina 5-ht2a uteis para a profilaxia e tratamento de desordens relacionadas com o mesmo
TWI415845B (zh) * 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
US20100292288A1 (en) * 2007-06-08 2010-11-18 Arena Pharmaceuticals, Inc. Crystalline forms of (r)-1-{2-[4`- (3-methoxy-propane-1- sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto
ES2421237T7 (es) 2007-08-15 2013-09-30 Arena Pharmaceuticals, Inc. Derivados de imidazo[1,2-a]piridin como moduladores del receptor serotoninérgico 5ht2a en el tratamiento de trastornos relacionados con el mismo
US20110021538A1 (en) * 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
CA2719373A1 (en) * 2008-04-16 2009-10-22 Arena Pharmaceuticals, Inc. Processes useful for the synthesis of (r)-1-{2-[4'-(3-methoxypropane-1-sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine
PT2364142T (pt) 2008-10-28 2018-04-23 Arena Pharm Inc Composições de um modulador do recetor da serotonina 5-ht2a para o tratamento de distúrbios com ele relacionados
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
GB201005511D0 (en) 2010-03-31 2010-05-19 Takeda Pharmaceutical Compounds and their use
FR2974729B1 (fr) * 2011-05-02 2013-04-19 Servier Lab Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
PT3309150T (pt) * 2013-01-09 2021-08-31 Arena Pharm Inc Ácido (r)-3-(4'-(2-(2-metilpirrolidin-1-il)etil)bifenil-4-il)propanoico como moduladores do recetor de histamina h3 para o tratamento de distúrbios cognitivos
RU2017145976A (ru) 2015-06-12 2019-07-15 Аксовант Сайенсиз Гмбх Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна
KR20180064373A (ko) 2015-07-15 2018-06-14 엑소반트 사이언시즈 게엠베하 신경퇴행성 질환과 관련된 환각의 예방 및 치료에 유용한 5-ht2a 세로토닌 수용체의 조절자로서의 다이아릴 및 아릴헤테로아릴 우레아 유도체
WO2020092604A1 (en) * 2018-10-30 2020-05-07 Concert Pharmaceuticals, Inc. Deuterated pitolisant
EP4251148A1 (en) 2020-11-27 2023-10-04 Richter Gedeon Nyrt. Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder
CN115160584B (zh) * 2022-07-06 2024-03-22 西北工业大学 一种基于阳离子-π与静电作用协同构筑异质孔超分子有机框架及制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217986A (en) * 1992-03-26 1993-06-08 Harbor Branch Oceanographic Institution, Inc. Anti-allergy agent
US5352707A (en) * 1992-03-26 1994-10-04 Harbor Branch Oceanographic Institution, Inc. Method for treating airway congestion
ATE264323T1 (de) * 1992-09-14 2004-04-15 Takeda Chemical Industries Ltd Heterocyclische verbindungen und ihre verwendung als angiotensin ii antagonisten
US5541217A (en) * 1995-05-17 1996-07-30 Ortho Pharmaceutical Corporation 4-arylcyclopenta[c]pyrrole analgesics
US5869479A (en) * 1997-08-14 1999-02-09 Schering Corporation Treatment of upper airway allergic responses
DE19937537A1 (de) * 1999-08-09 2001-03-08 Gruenenthal Gmbh Substituierte 2-Dialkylaminoalkylbiphenyl-Derivate
US20040044029A1 (en) * 2002-08-14 2004-03-04 Dart Michael J. Azabicyclic compounds are central nervous system active agents
US7244852B2 (en) * 2003-02-27 2007-07-17 Abbott Laboratories Process for preparing 2-methylpyrrolidine and specific enantiomers thereof
GB0308333D0 (en) * 2003-04-10 2003-05-14 Glaxo Group Ltd Novel compounds
JP4777974B2 (ja) * 2004-04-01 2011-09-21 イーライ リリー アンド カンパニー ヒスタミンｈ３受容体作用物質、製剤および治療的使用
US20050245543A1 (en) * 2004-04-30 2005-11-03 Pfizer Inc Histamine-3 receptor antagonists
US7145005B2 (en) * 2004-05-12 2006-12-05 Abbott Laboratories 2-(6-{2-[(2R)-2-Methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one salts and their preparation
AU2005280921B2 (en) * 2004-09-07 2011-05-19 Msd K.K. Carbamoyl-substituted spiro derivative
MX2007006387A (es) * 2004-12-03 2007-06-20 Hoffmann La Roche Derivados de piridina 3-substituidos como antagonistas h3.
MX2007008676A (es) * 2005-01-19 2007-07-25 Hoffmann La Roche Derivados de 5-aminoindol.
US20060188960A1 (en) * 2005-02-18 2006-08-24 Waters Stephen M Chimeric histamine H3 receptor
PL1899334T3 (pl) * 2005-06-17 2009-04-30 Janssen Pharmaceutica Nv Związki naftyrydynowe
EA014370B1 (ru) * 2005-09-16 2010-10-29 Янссен Фармацевтика Н.В. Циклопропиламины в качестве модуляторов рецептора гистамина н
DE602006020482D1 (de) * 2005-11-30 2011-04-14 Hoffmann La Roche 1,5-substituierte indol-2-yl amidderivative
AR058558A1 (es) * 2005-12-21 2008-02-13 Schering Corp Derivados de anilina sustituida utiles como antagonistas de la histamina h3
JP2009530274A (ja) * 2006-03-15 2009-08-27 ワイス ヒスタミン−３アンタゴニストとしてのｎ−置換−アザシクリルアミン化合物
WO2007136668A2 (en) * 2006-05-19 2007-11-29 Wyeth N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
CA2653940C (en) * 2006-05-30 2015-07-14 Janssen Pharmaceutica N.V. Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
WO2008005338A1 (en) * 2006-06-29 2008-01-10 Arena Pharmaceuticals, Inc. Modulators of the histamine h3-receptor useful for the treatment of disorders related thereto
US7648979B2 (en) * 2007-02-07 2010-01-19 Hoffmann-La Roche Inc. 5-amido-(1H-indol-2-yl)-piperazin-1-yl-methanone derivatives
US7557108B2 (en) * 2007-02-07 2009-07-07 Hoffmann-La Roche Inc. (Indol-4-yl) or (indol-5-yl)-piperazinylmethanones
US7507736B2 (en) * 2007-02-07 2009-03-24 Hoffmann-La Roche Inc. Indol-2-yl-piperazin-1-yl-methanone derivatives
WO2008144305A1 (en) * 2007-05-18 2008-11-27 Janssen Pharmaceutica N.V. Diaryl-substituted tetrahydroisoquinolines as histamine h3 receptor and serotonin transporter modulators
TW200901983A (en) * 2007-05-24 2009-01-16 Wyeth Corp Azacyclylbenzamide derivatives as histamine-3 antagonists
BRPI0817061A2 (pt) * 2007-09-12 2015-03-24 Wyeth Llc Derivados de pirrolidinilalquilisoquinolinona e -isoindolinona como antagonistas de histamina-3
TW200918062A (en) * 2007-09-12 2009-05-01 Wyeth Corp Azacyclylisoquinolinone and-isoindolinone derivatives as histamine-3 antagonists
US20090131417A1 (en) * 2007-11-20 2009-05-21 Letavic Michael A Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
WO2009143153A1 (en) * 2008-05-23 2009-11-26 Janssen Pharmaceutica Nv Substituted pyrrolidine amides as modulators of the histamine h3 receptor
US20100130477A1 (en) * 2008-11-25 2010-05-27 Astrazeneca Ab Spirocyclobutyl Piperidine Derivatives

Also Published As

Publication number Publication date
WO2008048609A1 (en) 2008-04-24
MX2009004071A (es) 2009-04-28
PA8750901A1 (es) 2009-03-31
TW200823204A (en) 2008-06-01
US20100240653A1 (en) 2010-09-23
AR063226A1 (es) 2009-01-14
KR20090069333A (ko) 2009-06-30
PE20081462A1 (es) 2008-10-18
EP2074086A1 (en) 2009-07-01
JP2010506918A (ja) 2010-03-04
EP2074086B1 (en) 2011-06-15
IL197892A0 (en) 2009-12-24
ATE512948T1 (de) 2011-07-15
CA2665204A1 (en) 2008-04-24
CL2007002977A1 (es) 2008-06-06
AU2007313180A1 (en) 2008-04-24

Similar Documents

Publication Publication Date Title
EA200970386A1 (ru) Бифенилсульфонильные и фенилгетероарилсульфонильные модуляторы гистаминового н3-рецептора, используемые для лечения ассоциированных с ним расстройств
BRPI0507374A (pt) moduladores do receptor de histamina-3
NZ595625A (en) Substituted 2-mercaptoquinoline-3-carboxamides as kcnq2/3 modulators
EA200901546A1 (ru) Дизамещенные амиды для усиления глутаматергических синаптических ответов
EA200800946A1 (ru) Антагонисты рецептора гистамина-3
BRPI0513486A (pt) derivados de cicloamino 1,3 substituìdo e seu emprego como antagonistas de receptor de histamina-3
WO2008153958A3 (en) Crystalline forms of (r)-1-{2-[4'- (3-methoxy-propane-1- sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto
BRPI0513444A (pt) antagonistas do receptor da histamina 3
NZ573565A (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
EA201070903A1 (ru) Замещенные спироциклические производные пиперидина как лиганды гистамин-3(h) рецептора
SG163526A1 (en) Bicyclic amides for enhancing glutamatergic synaptic responses
EA201000516A1 (ru) 3-замещенные 1,2,3-триазин-4-оны и 3-замещенные 1,3-пиримидин-оны для усиления глутаматергических синаптических ответов
JP2010529130A5 (ru)
HK1145834A1 (en) Phenylpyrazole derivatives
RU2011103759A (ru) Замещенные 6-(1-пиперазинил)-пиридазины в качестве антагонистов 5-нт6 рецептора
DOP2011000130A (es) 1-(arilsulfonil)-4-(pepirazin-1-il)-1h-benzimidazol como ligando de 5-hidroxitriptamina-6
BRPI0808353B8 (pt) usos de amidas do ácido 3-aril-3-hidróxi-2-amino-propiônico, amidas do ácido 3-heteroaril-3-hidróxi-2-amino-propiônico e compostos relacionados
BRPI0514820A (pt) antagonistas de receptor de histamina-3 amina azabicìclicos
HUP0400398A2 (hu) 2-[3,5-bisz-(Trifluor-metil)-fenil]-N-[6-(1,1-dioxo-1lambda6-tiomorfolin-4-il)-4-(2-metil- vagy-4-fluor-2-metil-helyettesített)-fenil-piridin-3-il]-N-metil-izobutiramid, eljárás az előállítására és ezeket tartalmazó gyógyszerkészítmények
EA202092979A1 (ru) Способ лечения обратным агонистом гистаминового рецептора 3 типа
ATE394122T1 (de) Hemmung des cd95 liganden/rezeptor-systems zur behandlung von neurologischen erkrankungen und verletzungen
JP2019535715A5 (ru)
TH102412A (th) สารควบคุมชนิดไบเฟนิลซัลโฟนิล และเฟนิล-เฮทเทโรแอริลซัลโฟนิลของฮีสทามีน h3-รีเซปเตอร์ที่มีประโยชน์สำหรับการรักษาความผิดปกติที่เกี่ยวข้องกับรีเซปเตอร์นั้น
CY1114789T1 (el) Ανταγωνιστες υποδοχεα ισταμινης-3
Ramesh Light at the end of the tunnel: a front-line clinician's personal narrative on COVID-19 and mental illness–Reflection